Primary Effusion Lymphoma

Is Dose-Adjusted-EPOCH Worthwhile Therapy?

Kegan Jessamy, Fidelis Ojevwe, Ravi Doobay, Rana Naous, John Yu, Sheila M. Lemke

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Primary effusion lymphoma (PEL) is a rare condition, which accounts for approximately 4% of all human immunodeficiency virus (HIV)-associated non-Hodgkin lymphomas. PEL has a predilection for body cavities and occurs in the pleural space, pericardium, and peritoneum. Without treatment, the median survival is approximately 2-3 months, and with chemotherapy, the median survival is approximately 6 months. We describe the case of a 47-year-old male with HIV and Kaposi's sarcoma who presented with complaints of abdominal pain and distension and was subsequently diagnosed with PEL. Despite limited clinical data being available, chemotherapy with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) has proven to increase survival rates in patients with this condition.

Original languageEnglish (US)
Pages (from-to)273-279
Number of pages7
JournalCase Reports in Oncology
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Primary Effusion Lymphoma
Vincristine
Etoposide
Prednisone
Doxorubicin
Cyclophosphamide
HIV
Drug Therapy
Survival
Kaposi's Sarcoma
Peritoneum
Pericardium
Non-Hodgkin's Lymphoma
Abdominal Pain
Therapeutics
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Jessamy, K., Ojevwe, F., Doobay, R., Naous, R., Yu, J., & Lemke, S. M. (2016). Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy? Case Reports in Oncology, 9(1), 273-279. https://doi.org/10.1159/000446315
Jessamy, Kegan ; Ojevwe, Fidelis ; Doobay, Ravi ; Naous, Rana ; Yu, John ; Lemke, Sheila M. / Primary Effusion Lymphoma : Is Dose-Adjusted-EPOCH Worthwhile Therapy?. In: Case Reports in Oncology. 2016 ; Vol. 9, No. 1. pp. 273-279.
@article{0421fb276a804c04bd2d8f1a5a6c7c15,
title = "Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?",
abstract = "Primary effusion lymphoma (PEL) is a rare condition, which accounts for approximately 4{\%} of all human immunodeficiency virus (HIV)-associated non-Hodgkin lymphomas. PEL has a predilection for body cavities and occurs in the pleural space, pericardium, and peritoneum. Without treatment, the median survival is approximately 2-3 months, and with chemotherapy, the median survival is approximately 6 months. We describe the case of a 47-year-old male with HIV and Kaposi's sarcoma who presented with complaints of abdominal pain and distension and was subsequently diagnosed with PEL. Despite limited clinical data being available, chemotherapy with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) has proven to increase survival rates in patients with this condition.",
author = "Kegan Jessamy and Fidelis Ojevwe and Ravi Doobay and Rana Naous and John Yu and Lemke, {Sheila M.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1159/000446315",
language = "English (US)",
volume = "9",
pages = "273--279",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "1",

}

Jessamy, K, Ojevwe, F, Doobay, R, Naous, R, Yu, J & Lemke, SM 2016, 'Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?', Case Reports in Oncology, vol. 9, no. 1, pp. 273-279. https://doi.org/10.1159/000446315

Primary Effusion Lymphoma : Is Dose-Adjusted-EPOCH Worthwhile Therapy? / Jessamy, Kegan; Ojevwe, Fidelis; Doobay, Ravi; Naous, Rana; Yu, John; Lemke, Sheila M.

In: Case Reports in Oncology, Vol. 9, No. 1, 01.01.2016, p. 273-279.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Primary Effusion Lymphoma

T2 - Is Dose-Adjusted-EPOCH Worthwhile Therapy?

AU - Jessamy, Kegan

AU - Ojevwe, Fidelis

AU - Doobay, Ravi

AU - Naous, Rana

AU - Yu, John

AU - Lemke, Sheila M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Primary effusion lymphoma (PEL) is a rare condition, which accounts for approximately 4% of all human immunodeficiency virus (HIV)-associated non-Hodgkin lymphomas. PEL has a predilection for body cavities and occurs in the pleural space, pericardium, and peritoneum. Without treatment, the median survival is approximately 2-3 months, and with chemotherapy, the median survival is approximately 6 months. We describe the case of a 47-year-old male with HIV and Kaposi's sarcoma who presented with complaints of abdominal pain and distension and was subsequently diagnosed with PEL. Despite limited clinical data being available, chemotherapy with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) has proven to increase survival rates in patients with this condition.

AB - Primary effusion lymphoma (PEL) is a rare condition, which accounts for approximately 4% of all human immunodeficiency virus (HIV)-associated non-Hodgkin lymphomas. PEL has a predilection for body cavities and occurs in the pleural space, pericardium, and peritoneum. Without treatment, the median survival is approximately 2-3 months, and with chemotherapy, the median survival is approximately 6 months. We describe the case of a 47-year-old male with HIV and Kaposi's sarcoma who presented with complaints of abdominal pain and distension and was subsequently diagnosed with PEL. Despite limited clinical data being available, chemotherapy with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) has proven to increase survival rates in patients with this condition.

UR - http://www.scopus.com/inward/record.url?scp=84969972591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969972591&partnerID=8YFLogxK

U2 - 10.1159/000446315

DO - 10.1159/000446315

M3 - Article

VL - 9

SP - 273

EP - 279

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 1

ER -

Jessamy K, Ojevwe F, Doobay R, Naous R, Yu J, Lemke SM. Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy? Case Reports in Oncology. 2016 Jan 1;9(1):273-279. https://doi.org/10.1159/000446315